In this first part of a video series, Susan Cantrell, CEO of AMCP, discussed root causes of high drug prices, its impact on underserved communities and Medicare price negotiation, emphasizing AMCP's actions and the role of decreasing drug prices for equity.
Results of the evaluations will inform recommendations to payers and providers about whether and how to adopt these technologies.
One of the nation’s largest not for profit Medicare Advantage plans, SCAN Health Plan, is the first to use the feature.
Adolescent uptake levels of PrEP are low among adolescents ages 16-24 years old.
How health plans and self-insured employers coped with the huge number of prescriptions for weight loss. It started with off-label Ozempic (semaglutide) and now there’s FDA-approved Wegovy (semaglutide) and Zepbound (tirzepatide).
Some changes sparked debate among groups.
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Biktarvy can now be used to treat people with HIV who have a known or suspected M184V/I mutation, a common form of treatment resistance.
High costs and prior authorization impact beneficiaries’ ability to access care. Some said they had to wait more than a month to see a doctor.
Participation in the program will not be a prerequisite for GLP-1 prescriptions.
Share your view about the Change Healthcare cyberattack.
Researchers say the open-label extension of their study suggests the response to Xolair (omalizumab) will be a durable, but an accompanying editorial says that “protection will most likely disappear” after treatment is stopped.
Duke researchers tested a program that involves hair stylists in raising awareness, possible uptake of HIV preexposure prophylaxis (PrEP) among Black women, a group that is disproportionately affected by new HIV infections.
The FDA has removed the approval of Pepaxto in multiple myeloma. The agency approved Amtagvi, the first TIL therapy for a solid tumor, as well a new biweekly dosing of Tecvayli for multiple myeloma. The agency has set actions for several products, including a first-in-class lung cancer therapy, a bispecific antibody for advanced multiple myeloma, and another for Dupixent for COPD
In this month’s episode of Tuning In to the C-Suite, Briana Contreras, an editor of Managed Healthcare Executive, got to chatting with Sanjula Jain, Ph.D., chief research officer at Trilliant Health.
The information systems of Change Healthcare, a recently acquired subsidiary of UnitedHealth Group, were disconnected on Wednesday.
The results of this week’s poll about Medicaid work requirements.
A study suggests that a novel CAR T-cell therapy could be a curative treatment for some patients with chronic lymphocytic leukemia, with 25% of responders still in remission after 6 years.
The economy and healthcare costs are the issues voters want to hear about going into the 2024 presidential election, finds a survey by KFF.
The greatest savings are seen for 90-tablet prescriptions.
Research results reported in the journal Science today add to the evidence that “immunogenetics” likely influences people’s susceptibility to developing lung cancer, especially among smokers.
A coalition of women, including members of the Democratic Women’s Caucus (DWC), Pro-Choice Caucus Contraception & Family Planning Task Force, and Senators, took the lead in rallying over 150 House and Senate Democratic colleagues, after the large group of lawmakers wrote a letter yesterday to America’s Health Insurance Plans (AHIP) President and CEO Mike Tuffin addressing that AHIP’s “members are not complying with the Affordable Care Act contraception coverage requirement.."
Because of expensive specialty drugs, pharmacy expenditures accounted for one-quarter of healthcare spending by public sector health plans, according to a new report by two public sector health plan groups.
This new initiative brings together provider groups, purchasers and end users committed to evidence-based, cost-effective, equitable digital health solutions.
Research and development funding increased in 2023 but clinical trial starts fell by 15%, partly because of fewer COVID-19-related trials, according to IQVIA's worldwide report on research and development in the biopharmaceutical industry.
New insight could change the way physicians treat disorders like insomnia.
Official recommendations from the American Gastroenterological Association.
There was a record-breaking total of 725 breaches in 2023.
